Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07619287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

Name: An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies — clinical trial record (NCT07619287)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorBeOne Medicines

Started2026-06-23

View on ClinicalTrials.gov ↗

Amendment history

2026-09-10

Study Status, Contacts/Locations v6

Trial sites expanded: 13 → 16 locations

2026-08-17

Study Status, Contacts/Locations v5

Trial sites expanded: 10 → 13 locations

2026-08-06

Study Status, Contacts/Locations v4

Trial sites expanded: 7 → 10 locations

2026-08-03

Study Status, Contacts/Locations v3

Trial sites expanded: 4 → 7 locations

2026-07-07

Study Status, Contacts/Locations v2

Trial sites expanded: 1 → 4 locations

2026-06-26

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-06-01→confirmed 2026-06-23

Study sites0→1

2026-05-22

Original filing

BeOne Medicines

59 trials monitored

See 7 trials at risk

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

Trial Details

NCT Number	NCT07619287
Lead Sponsor	BeOne Medicines
Conditions	Myeloid Malignancy
Enrollment	118 participants
Start Date	2026-06-23
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-28